← All trials
NCT04810533
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2020
- Primary completion
- Mar 5, 2021
- Completion date
- Mar 5, 2021
- First posted
- Mar 23, 2021
- Last posted
- Mar 23, 2021
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Lead sponsor
- Nanjing Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.